Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
35.00M | 371.21M | 436.00K | 913.08M | 543.00K | Gross Profit |
37.31M | 240.96M | -109.81M | 895.13M | -268.86M | EBIT |
-466.57M | -222.54M | -673.16M | 373.53M | -354.44M | EBITDA |
-466.57M | -202.70M | -648.99M | 391.48M | -345.25M | Net Income Common Stockholders |
-366.25M | -153.61M | -650.17M | 377.66M | -348.87M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.90B | 1.69B | 1.82B | 2.38B | 1.69B | Total Assets |
2.24B | 2.23B | 2.24B | 2.75B | 1.83B | Total Debt |
223.69M | 238.63M | 244.02M | 225.03M | 61.43M | Net Debt |
-74.56M | -150.84M | 32.14M | -698.00M | -1.11B | Total Liabilities |
309.95M | 346.77M | 367.58M | 352.42M | 163.73M | Stockholders Equity |
1.93B | 1.88B | 1.88B | 2.40B | 1.66B |
Cash Flow | Free Cash Flow | |||
-144.68M | -272.35M | -532.93M | 457.27M | -256.72M | Operating Cash Flow |
-142.77M | -260.38M | -495.74M | 538.97M | -238.37M | Investing Cash Flow |
-280.48M | 374.65M | -258.65M | -1.04B | -541.17M | Financing Cash Flow |
331.98M | 62.66M | 38.59M | 250.94M | 1.02B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $2.80B | ― | -19.20% | ― | -89.95% | -123.71% | |
46 Neutral | $1.64B | ― | -43.94% | ― | -83.18% | -144.95% | |
42 Neutral | $139.84M | ― | -187.83% | ― | -67.20% | 64.66% | |
41 Neutral | $713.24M | ― | -54.00% | ― | 59.55% | 3.09% | |
39 Underperform | $92.93M | ― | -98.10% | ― | -58.64% | -40.05% | |
39 Underperform | $341.42M | ― | -36.36% | ― | 174.98% | 25.06% |
On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.